Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 2:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 98 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Stage1: Placebo Clear all
Terminated Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Volunteers and COPD Patients to Evaluate the Efficacy and Safety of Inhaled TV46017

NCT02315131
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD
Interventions
TV46017, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
20 Years to 75 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
2
States / cities
St Louis, Missouri • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 1, 2026, 2:26 AM EDT
Withdrawn Phase 2 Interventional

Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial

NCT07349771
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Axatilimab, Biospecimen Collection, Bone Marrow Aspiration, Computed Tomography, Cyclophosphamide, Magnetic Resonance Imaging, Mycophenolate Mofetil, Placebo Administration, Positron Emission Tomography, Skin Biopsy, Tacrolimus, X-Ray Imaging
Procedure · Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 1, 2026, 2:26 AM EDT
Completed Phase 3 Interventional Results available

Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants

NCT03881696
View directory record Official record
Conditions
Peanut Allergy, Multi-food Allergy
Interventions
Omalizumab, Placebo for Omalizumab, Multi-Allergen Oral Immunotherapy, Placebo for Multi-Allergen Oral Immunotherapy, Double-Blind Placebo-Controlled Food Challenge Based Treatment
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Year to 55 Years
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
10
States / cities
Little Rock, Arkansas • Stanford, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 1, 2026, 2:26 AM EDT
Completed Phase 3 Interventional Results available

CHAMP: Study of NVK-002 in Children With Myopia

NCT03350620
View directory record Official record
Conditions
Myopia
Interventions
NVK-002 Concentration 1, NVK-002 Concentration 2, Placebo
Drug
Lead sponsor
Vyluma, Inc.
Industry
Eligibility
3 Years to 17 Years
Enrollment
670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
20
States / cities
Tucson, Arizona • Berkeley, California • Fullerton, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 1, 2026, 2:26 AM EDT
Completed Phase 1 Interventional

Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis.

NCT00308243
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Sodium Pyruvate in 0.9% Sodium Chloride Solution
Drug
Lead sponsor
Emphycorp
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 19, 2011 · Synced Oct 1, 2026, 2:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of 7 Days of Grape Seed Extract Supplementation on Cold Pressor Test and Muscle Metaboreflex in Individuals With Elevated and Stage 1 Hypertension

NCT06428890
View directory record Official record
Conditions
Prehypertension
Interventions
Grape Seed Extract, Placebo
Dietary Supplement
Lead sponsor
California Baptist University
Other
Eligibility
18 Years to 30 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Riverside, California
Source: ClinicalTrials.gov public record
Updated May 24, 2024 · Synced Oct 1, 2026, 2:26 AM EDT
Terminated Phase 2 Interventional Results available

Aspirin to Prevent Preeclampsia in Women With Elevated Blood Pressure and Stage 1 Hypertension (ASPPIRE)

NCT04402385
View directory record Official record
Conditions
Pre-Eclampsia, Stage 1 Hypertension, Elevated Blood Pressure
Interventions
Aspirin 81 mg, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Oct 1, 2026, 2:26 AM EDT
Withdrawn Phase 3 Interventional

Clevidipine vs Placebo or Standard of Care for Dyspnea and Blood Pressure Control in AHF

NCT04592380
View directory record Official record
Conditions
Dyspnea, Hypertension, Acute Heart Failure
Interventions
Stage 1: Clevidipine (double-blinded), Stage 1: Placebo (double-blinded), Stage 2: Clevidipine (open-label), Stage 2: Standard of Care (open-label)
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
9
States / cities
Montgomery, Alabama • Tucson, Arizona • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 1, 2026, 2:26 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

An Efficacy and Safety Profile of Inhaled TV48108 in Healthy Volunteers and COPD Patients

NCT02315144
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
TV48108, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
20 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
2
States / cities
Medford, Oregon • Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 1, 2026, 2:26 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Study of the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% Dual Inactivation and Filtration (DIF) in Participants With Post-polio Syndrome

NCT02176863
View directory record Official record
Conditions
Post-polio Syndrome
Interventions
Flebogamma® 5% DIF, Placebo
Biological · Drug
Lead sponsor
Instituto Grifols, S.A.
Industry
Eligibility
18 Years to 75 Years
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
4
States / cities
St Louis, Missouri • Syracuse, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 1, 2026, 2:26 AM EDT
Completed Phase 3 Interventional

Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Diabetic Polyneuropathy (Stage 1 or 2)

NCT00977483
View directory record Official record
Conditions
Diabetic Polyneuropathy
Interventions
Thioctic Acid, Placebo
Drug
Lead sponsor
MEDA Pharma GmbH & Co. KG
Industry
Eligibility
18 Years to 64 Years
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
25
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Oct 1, 2026, 2:26 AM EDT
Terminated Phase 2 Interventional Results available

POC Study in Partially Responsive Generalized Anxiety Disorder

NCT02310568
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
PF-06372865.
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
47
States / cities
Cerritos, California • Encino, California • Imperial, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 1, 2026, 2:26 AM EDT
Not yet recruiting Phase 3 Interventional

A Study to Evaluate the Maintenance of Efficacy and Long-term Safety of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)

NCT07733947
View directory record Official record
Conditions
Subcutaneous Fat
Interventions
CBL-514 Injection, 0.9 % sodium chloride
Drug
Lead sponsor
Caliway Biopharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Encinitas, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 1, 2026, 2:26 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older

NCT04904549
View directory record Official record
Conditions
COVID-19
Interventions
SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent D614) (primary series), SARS-CoV-2 adjuvanted recombinant protein vaccine (bivalent D614 + B.1.351) (primary series), Placebo, SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent B.1.351) (booster dose) >= 4 months after last vaccination, SARS-CoV-2 adjuvanted recombinant protein vaccine(monovalent D614)(primary series)& SARS-CoV-2 adjuvanted recombinant protein vaccine(monovalent B.1.351)(booster dose)>=4 months after last vaccination
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
23,670 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
23
States / cities
Birmingham, Alabama • Huntsville, Alabama • Rolling Hills Estates, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 1, 2026, 2:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of GT20029

NCT05428449
View directory record Official record
Conditions
Androgenetic Alopecia, Acne Vulgaris
Interventions
GT20029 Gel, GT20029 Gel Placebo
Drug
Lead sponsor
Suzhou Kintor Pharmaceutical Inc,
Industry
Eligibility
18 Years to 60 Years
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
San Diego, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 1, 2026, 2:26 AM EDT
Completed Phase 2 Interventional

Blueberry Consumption Improves Vascular Function and Lowers Blood Pressure in Postmenopausal Women With Pre- and Stage 1-hypertension

NCT01686282
View directory record Official record
Conditions
Blood Pressure
Interventions
Freeze-dried Blueberry Powder, Placebo
Dietary Supplement
Lead sponsor
Florida State University
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Jan 14, 2015 · Synced Oct 1, 2026, 2:26 AM EDT
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

NCT06647498
View directory record Official record
Conditions
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Interventions
Remternetug, Matching Placebo (Remternetug)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2034
U.S. locations
13
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 1, 2026, 2:26 AM EDT
Recruiting Phase 2Phase 3 Interventional

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT06236438
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Livmoniplimab, Budigalimab, Pembrolizumab, Pemetrexed, Cisplatin, Carboplatin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
19
States / cities
La Jolla, California • Pembroke Pines, Florida • Winter Haven, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 1, 2026, 2:26 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase 1b/2 Trial of the Safety and Microbiological Activity of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized With Pseudomonas Aeruginosa

NCT05453578
View directory record Official record
Conditions
Bacterial Disease Carrier, Cystic Fibrosis
Interventions
Placebo, WRAIR-PAM-CF1
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
19
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 1, 2026, 2:26 AM EDT
Terminated Phase 3 Interventional Results available

Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency

NCT02722304
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Alpha1-antitrypsin Deficiency
Interventions
ARALAST NP 60 mg/kg, ARALAST NP 120 mg/kg, GLASSIA 60 mg/kg, GLASSIA 120 mg/kg, Human Albumin 2%
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
14
States / cities
Peoria, Arizona • Newport Beach, California • Kissimmee, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 1, 2026, 2:26 AM EDT
Completed Phase 4 Interventional

A Randomized, Double-blind, Placebo Controlled Comparison of Telmisartan Hydrochlorothiazide (HCT) and Valsartan HCT in Hypertension (HTN) Stage I/II Patients

NCT00240448
View directory record Official record
Conditions
Hypertension
Interventions
telmisartan 80 mg/hydrochlorothiazide 25 mg, valsartan 160 mg/hydrochlorothiazide 25 mg, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
100
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 90 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Oct 1, 2026, 2:26 AM EDT
Recruiting Phase 2 Interventional

BLOCK-SAH - PPF-Block for Post-SAH Headache

NCT06008795
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Aneurysmal, Headache
Interventions
Pterygopalatine Fossa Nerve Block with Ropivacaine and Dexamethasone, Placebo Pteryogpalatine Fossa Injection
Drug · Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 85 Years
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
13
States / cities
Gainesville, Florida • Miami, Florida • Stuart, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 1, 2026, 2:26 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Telapristone Acetate (Proellex®) in the Treatment of Pre-Menopausal Women With Confirmed, Symptomatic Endometriosis

NCT01728454
View directory record Official record
Conditions
Endometriosis
Interventions
Placebo, Telapristone acetate
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 47 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
10
States / cities
Tucson, Arizona • Little Rock, Arkansas • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 1, 2026, 2:26 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Study of a Respiratory Syncytial Virus Candidate Encapsulated in a Lipid Nanoparticle Based Formulation in Adults Aged 18 to 50 Years and 60 Years and Older

NCT05639894
View directory record Official record
Conditions
Respiratory Syncytial Virus Immunization
Interventions
RSV vaccine candidate, Placebo
Biological · Other
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
865 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
25
States / cities
Huntsville, Alabama • Mesa, Arizona • Peoria, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 1, 2026, 2:26 AM EDT